

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 4, 2007

Access Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware 0-9314 83-0221517

(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)

2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (214) 905-5100

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:

// Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

// Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)

// Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2 (b))

// Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4 (c))

Item 1.01

Entry into a Material Definitive Agreement

Item 5.02

Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.

On January 8, 2007, the Company announced that Stephen R. Seiler has been named by the Company's Board of Directors as the Company's President and Chief Executive Officer and director, effective as of January 4, 2007 (the "Effective Date"). Mr. Seiler entered into an Employment Agreement with the Company, dated the Effective Date (the "Employment Agreement"). Mr. Seiler's title will be President and Chief Executive Officer. Mr. Seiler will be paid an annual salary of \$350,000 and was granted stock options to purchase 500,000 shares of the Company's common stock with an exercise price equal to the closing price of the Company's common stock on the day preceding the Effective Date. Mr. Seiler's options will vest 25% on January 4, 2008 and monthly thereafter over a 36 month period. The

stock options are granted from the Company's 2005 Equity Incentive Plan and the 2007 Supplemental Option Plan. Mr. Seiler is entitled to similar employee benefits as the Company's other executive officers. Under certain circumstances relating to a change of control of the Company, Mr. Seiler may be entitled to receive a payment equal to his annual salary, acceleration of options and extension of health care benefits.

Mr. Seiler, age 50, has until recently been Acting Chief Executive Officer of Effective Pharmaceuticals, Inc. and advising other companies in the healthcare field. From 2001 until 2004 he was Chief Executive Officer of Hybridon, Inc. (currently Idera Pharmaceuticals, Inc.). Mr. Seiler was Executive Vice President, Planning, Investment & Development at Elan Corporation plc from 1995 until 2001. He also worked as an investment banker at Paribus Capital Markets in both London and New York from 1991 to 1995 where he was founder and head of Paribus's pharmaceutical investment banking group. Mr. Seiler received a B.A. in History from the University of Notre Dame in 1977 and a J.D. from Georgetown University in 1980.

Also on January 8, 2007, the Company announced that Rosemary Mazanet, MD, PhD, director, resigned as Acting CEO of the Company was appointed Vice-Chairman of the Company's Board of Directors, as of the Effective Date.

Also on January 8, 2007, the Company announced that David P. Luci was appointed a member of the Company's Board of Directors and Audit Committee Chairman, as of the Effective Date.

Mr. Luci is Executive Vice President and General Counsel of Bioenvision, Inc., a product-oriented biopharmaceutical company. He has been with Bioenvision from 2002 to the present and served as its CFO until December 31, 2006. From 1994 to 2002 he was an Associate with Paul, Hastings, Janofsky & Walker LLP. Prior to that time he was a Senior Auditor with Ernst & Young LLP. Mr. Luci holds a BS in Business Administration and a JD from Albany Law School of Union University.

A press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference, in which the Company announced its new President and CEO, Stephen R. Seiler, its new Vice-Chairman of its Board of Directors, Rosemary Mazanet, MD, PhD, and its new director David P. Luci.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Access Pharmaceuticals, Inc.
(Registrant)

By: /s/ Stephen B. Thompson

Stephen B. Thompson
Vice President and
Chief Financial Officer

Dated January 8, 2007

ACCESS NEWS

Contact: Company	Contact: Investor Relations
-----	-----
Stephen B. Thompson Vice President, Chief Financial Officer (214) 905-5100	Donald C. Weinberger/Alisa Steinberg (media) Wolfe Axelrod Weinberger LLC (212) 370-4500

ACCESS PHARMACEUTICALS NAMES
STEPHEN R. SEILER AS PRESIDENT AND CEO

- Rosemary Mazanet, MD, PhD appointed Vice-Chairman -

- David P. Luci joins Board of Directors -

Dallas, TEXAS, January 8, 2007, ACCESS PHARMACEUTICALS, INC. (ACCP.OB) announced today that Stephen R. Seiler has joined the Company to serve as President and Chief Executive Officer and has been named a member of the Board of Directors. Rosemary Mazanet, MD, PhD, former Acting CEO of Access, has been appointed Vice-Chairman of the Board and David P. Luci, C.P.A., Esq. has been appointed to the Board of Directors and agreed to serve as Audit Committee Chairman.

Mr. Seiler has until recently been Acting Chief Executive Officer of Effective Pharmaceuticals, Inc. and advising other companies in the healthcare field. From 2001 until 2004 he was Chief Executive Officer of Hybridon, Inc. (currently Idera Pharmaceuticals, Inc.). While at Hybridon, Mr. Seiler guided the company through capital raisings totaling over \$30 million, the restructuring of its senior securities, the re-listing of the company's stock on the American Stock Exchange, as well as several pharmaceutical licensing transactions. Mr. Seiler was Executive Vice President, Planning, Investment & Development at Elan Corporation plc from 1995 until 2001. He also worked as an investment banker at Paribus Capital Markets in both London and New York from 1991 to 1995 where he was

-More-

Access Pharmaceuticals, Inc.
Page 2

founder and head of Paribas's pharmaceutical investment banking group. Mr. Seiler received a B.A. in History from the University of Notre Dame in 1977 and a J.D. from Georgetown University in 1980.

Rosemary Mazanet, MD, PhD, former Acting CEO of Access, has been appointed Vice Chairman of the Board of Directors. She will retain an active role with the Company as a consultant particularly with respect to our clinical programs and business arrangements.

The Company also announced the appointment of David P. Luci, C.P.A., Esq. to serve on the Company's Board of Directors and as Audit Committee Chairman. Mr. Luci is Executive Vice President and General Counsel of Bioenvision, Inc., a product-oriented biopharmaceutical company. He has been with Bioenvision from 2002 to the present. From 1994 to 2002 he was an Associate with Paul, Hastings, Janofsky & Walker LLP. Prior to that time he was a Senior Auditor with Ernst & Young LLP. Mr. Luci holds a BS in Business Administration and a JD from Albany Law School of Union University.

"We are extremely pleased to have Stephen Seiler on board, both as CEO and director," stated Mr. Jeffrey B. Davis, Chairman of Access' Board of Directors. "Mr. Seiler has a unique blend of skills and experiences and is extremely well qualified to direct Access through its next stages of clinical and business development."

"We thank Dr. Rosemary Mazanet for her hard work and accomplishments

over the past 18 months and are very pleased that she has agreed to accept the role of Vice Chairman of the Board, and will continue to be an integral part of our ongoing development of ProLindac(TM), as well as other key clinical programs. We are also very happy to announce that Mr. David Luci has agreed to join the Access Board of Directors. David's unique experiences as Bioenvision's chief financial officer and chief counsel will serve our board extremely well," Mr. Davis continued.

Mr. Seiler added, "We plan to aggressively advance and broaden the Company's exciting drug portfolio including by the expansion of our Phase II clinical trials of ProLindac(TM) and the commercialization of MuGard(TM), which has recently received marketing clearance from the FDA for treatment of mucositis induced by cancer therapy. I look forward to working with Rosemary and the rest of the team at Access."

-More-

Access Pharmaceuticals, Inc.

Page 3

About ProLindac(TM)

The Company's lead compound, ProLindac(TM), is a novel dach platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. The Company believes that ProLindac's unique molecular design potentially could eliminate some of the toxic neurological side effects seen in currently marketed Dach platinums. The Company is currently enrolling patients in two Phase II clinical trials, one in ovarian cancer and one in head and neck cancer, and plans to initiate one or more additional Phase II trials, including one in colorectal cancer in 2007.

About MuGard(TM)

The Company has received 510(k) clearance from the FDA to market MuGard(TM) in the United States. MuGard(TM) is Access' proprietary oral rinse product for the prevention and treatment of oral mucositis, the debilitating side-effect which afflicts more than 40% of cancer patients undergoing radiation and chemotherapy. There is currently no well-accepted treatment for mucositis. Access is actively seeking marketing partners in Europe and the US.

About Vitamin B12

The Company is actively pursuing developing clinical development of its novel Vitamin B12 drug delivery technology, particularly as it pertains to the oral delivery of large molecule drugs that are only currently deliverable by injection or intravenous administration. Pre-clinical animal studies utilizing Access' VB-12 technology have demonstrated the ability to deliver insulin by oral administration in therapeutic levels. Access is actively seeking development partners in this area as well.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the treatment of patients with mucositis. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited

to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission.

###